{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 161,
  "pageCount": 236,
  "prevPage": 160,
  "nextPage": 162,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to expose a gap between Twist's marketing claims and customer reality regarding oligo length capabilities.",
  "elementsJson": [
    "paragraph",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/161",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-161",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "They stated that when Twist attempts larger oligos, it has to use standard technology and not its chip: “they cannot come up with these really long oligos”; “you only use that in the early, early stages of discovery which is mostly in academia...then you don’t use that technology anymore”; “they take much longer because they need to use another technology.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bff1-da5e8a3397b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Q: “Is there anything special about this synthesis chip? It’s the size of a well plate that has some kind of a silicon coating on it. If they can’t produce fast enough for you and at scale, I don’t really understand how it helps them.”\nA: “But the problem is that yeah, they have this - with all these different plaster surfaces - but I think they can also produce oligos up to 200 or 300 nucleotides, so they cannot come up with these really long oligos in that oligo pool.”\nQ: “And what about Thermo and IDT? Do other people produce longer oligos?”\nA: “Yes. When you need to produce genes and things, you need at least 1000, 2000, and even longer nucleotides. That pool that you mean, that oligo pool, that one is very useful for CRISPR libraries. But the problem is that these CRISPR libraries and the application of this tool are very limited. You only use that in the early, early stages of discovery, which is mostly in academia, biotech, or in some labs in the pharma. You use them, you discover a gene or a pathway, and then you move forward and then you don’t use that technology anymore.”\nQ: “You’re saying that Twist can’t even make longer oligos beyond 250, while the other vendors can?”\nA: “No. They can but not with this technology. “\nQ: “But do they sell oligos more than 250?”\nA: “They do sell oligos longer than 250, but then they take much longer because they need to use another technology. So, this oligo pool that you explained, that they claim that they can do things so fast and so many at once, is for small oligos, and this is for library preparation for the CRISPR.”\nQ: “Now I get why you order a lot more from Thermo and others. Can everybody do longer oligos faster etc. than Twist?”\nA: “Not everyone, but for sure, Sigma and Thermo can.”\nQ: “How about IDT and Genscript?”\nA: “Probably they can also do it faster. Genscript would probably be similar.” -Novartis, a large Twist customer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3135a373-7445-46c7-9c82-0ab0c944697d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Twist’s chip can only small oligos; useless for larger pools where use standard techniques; can only make short sequences that are 10% of the length needed; short sequences useless beyond early-stage, academic work",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed377f2c-3a4f-4601-9337-adb1695f2411",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“they cannot come up with these really long oligos”; “you only use that in the early, early stages of discovery which is mostly in academia, biotech, or in some labs in the pharma. You use them, you discover a gene or a pathway, and then you move forward and then you don’t use that technology anymore.”; “They do sell oligos longer than 250, but then they take much longer because they need to use another technology. So, this oligo pool that you explained, that they claim that they can do things so fast and so many at once, is for small oligos, and this is for library preparation for the CRISPR.” — Novartis, a large Twist customer",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bff1-dd6657feaae2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edd55b59-c4ce-43ad-b3e9-c50f82fdc5bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Novartis elaborated on Twist’s manufacturing failures, indicating that its chip can only make small oligos, while customers need ones that are 5-20X longer for more serious applications. They stated that when Twist attempts larger oligos, it has to use standard technology and not its chip: “they cannot come up with these really long oligos”; “you only use that in the early, early stages of discovery which is mostly in academia...then you don’t use that technology anymore”; “they take much longer because they need to use another technology.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08bb02a2-6687-4478-977c-3888403cd568",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "99df9bc7-a12d-41f7-a758-7137e1e2b3d8",
      "evidence": "The slide explicitly contrasts company claims with expert testimony to expose a technical limitation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}